RV 568

Drug Profile

RV 568

Alternative Names: JNJ 49095397; RV-568

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator RespiVert
  • Developer Janssen Biotech; RespiVert
  • Class Antiasthmatics; Antibronchitics; Antihistamines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • No development reported Asthma; Cystic fibrosis; Lung disorders; Seasonal allergic rhinitis

Most Recent Events

  • 22 Jul 2015 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation,Aerosol)
  • 01 Sep 2014 Janssen Research & Development completes a phase II trial for Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (inhalation) (NCT01867762)
  • 01 Sep 2013 Phase-II clinical trials in Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (Inhalation) after September 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top